CA3107401A1 - Gene signatures for predicting metastasis of melanoma and patient prognosis - Google Patents
Gene signatures for predicting metastasis of melanoma and patient prognosis Download PDFInfo
- Publication number
- CA3107401A1 CA3107401A1 CA3107401A CA3107401A CA3107401A1 CA 3107401 A1 CA3107401 A1 CA 3107401A1 CA 3107401 A CA3107401 A CA 3107401A CA 3107401 A CA3107401 A CA 3107401A CA 3107401 A1 CA3107401 A1 CA 3107401A1
- Authority
- CA
- Canada
- Prior art keywords
- individual
- gene expression
- plat
- itgb3
- gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862703221P | 2018-07-25 | 2018-07-25 | |
| US62/703,221 | 2018-07-25 | ||
| US201862750294P | 2018-10-25 | 2018-10-25 | |
| US62/750,294 | 2018-10-25 | ||
| US201862778777P | 2018-12-12 | 2018-12-12 | |
| US62/778,777 | 2018-12-12 | ||
| PCT/NL2019/050487 WO2020022895A2 (en) | 2018-07-25 | 2019-07-25 | Gene signatures for predicting metastasis of melanoma and patient prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107401A1 true CA3107401A1 (en) | 2020-01-30 |
Family
ID=68242821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107401A Pending CA3107401A1 (en) | 2018-07-25 | 2019-07-25 | Gene signatures for predicting metastasis of melanoma and patient prognosis |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12473599B2 (https=) |
| EP (1) | EP3827101B1 (https=) |
| JP (1) | JP7633159B2 (https=) |
| KR (1) | KR20210044233A (https=) |
| CN (1) | CN113039289B (https=) |
| AU (1) | AU2019310636B2 (https=) |
| CA (1) | CA3107401A1 (https=) |
| DK (1) | DK3827101T3 (https=) |
| ES (1) | ES2966015T3 (https=) |
| IL (1) | IL280377A (https=) |
| WO (1) | WO2020022895A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102751357B1 (ko) * | 2021-07-16 | 2025-01-06 | 한림대학교 산학협력단 | 구강암의 임프절 전이 예측과 관련된 유전자군 |
| WO2023107329A1 (en) * | 2021-12-08 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Assessing and treating melanoma |
| AU2022406744A1 (en) * | 2021-12-08 | 2024-07-11 | Mayo Foundation For Medical Education And Research | Assessing and treating melanoma |
| WO2024108191A1 (en) * | 2022-11-18 | 2024-05-23 | University Of Virginia Patent Foundation | Machine learning approach to predicting lymph node metastases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| AU2003298689A1 (en) | 2002-11-21 | 2004-06-18 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| US20070154889A1 (en) | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
| US20060136145A1 (en) | 2004-12-20 | 2006-06-22 | Kuo-Jang Kao | Universal reference standard for normalization of microarray gene expression profiling data |
| TW200719903A (en) | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
| NZ593226A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| AU2007292219B2 (en) | 2006-09-06 | 2014-04-24 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
| AU2008247502A1 (en) | 2007-05-04 | 2008-11-13 | Dermtech International | Diagnosis of melanoma by nucleic acid analysis |
| EP2191020A2 (en) | 2007-08-16 | 2010-06-02 | Genomic Health, Inc. | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
| AU2009221778A1 (en) | 2008-03-05 | 2009-09-11 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
| US20120128667A1 (en) | 2009-05-01 | 2012-05-24 | Oncozyme Pharma Inc. | Pentamidine combinations for treating cancer |
| US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| AU2011305696A1 (en) | 2010-09-20 | 2013-05-02 | Advanced Cell Diagnostics, Inc. | Biomarkers for differentiating melanoma from benign nevus in the skin |
| EP3195869B1 (en) | 2012-07-27 | 2021-09-29 | Agency for Science, Technology and Research (A*STAR) | Method of promoting wound healing |
| WO2014077915A1 (en) | 2012-11-14 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| WO2016025717A1 (en) * | 2014-08-14 | 2016-02-18 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| MX388345B (es) | 2016-05-10 | 2025-03-19 | Mayo Found Medical Education & Res | Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento. |
-
2019
- 2019-07-25 CA CA3107401A patent/CA3107401A1/en active Pending
- 2019-07-25 AU AU2019310636A patent/AU2019310636B2/en active Active
- 2019-07-25 ES ES19787488T patent/ES2966015T3/es active Active
- 2019-07-25 CN CN201980062825.7A patent/CN113039289B/zh active Active
- 2019-07-25 DK DK19787488.6T patent/DK3827101T3/da active
- 2019-07-25 WO PCT/NL2019/050487 patent/WO2020022895A2/en not_active Ceased
- 2019-07-25 KR KR1020217005548A patent/KR20210044233A/ko active Pending
- 2019-07-25 EP EP19787488.6A patent/EP3827101B1/en active Active
- 2019-07-25 JP JP2021528324A patent/JP7633159B2/ja active Active
- 2019-07-25 US US17/262,175 patent/US12473599B2/en active Active
-
2021
- 2021-01-24 IL IL280377A patent/IL280377A/en unknown
-
2025
- 2025-09-11 US US19/326,514 patent/US20260071281A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113039289A (zh) | 2021-06-25 |
| US12473599B2 (en) | 2025-11-18 |
| JP7633159B2 (ja) | 2025-02-19 |
| EP3827101B1 (en) | 2023-11-08 |
| WO2020022895A2 (en) | 2020-01-30 |
| NZ771988A (en) | 2025-02-28 |
| AU2019310636B2 (en) | 2025-06-26 |
| DK3827101T3 (da) | 2023-12-11 |
| EP3827101A2 (en) | 2021-06-02 |
| IL280377A (en) | 2021-03-25 |
| ES2966015T3 (es) | 2024-04-17 |
| KR20210044233A (ko) | 2021-04-22 |
| US20260071281A1 (en) | 2026-03-12 |
| WO2020022895A3 (en) | 2020-04-02 |
| US20210301353A1 (en) | 2021-09-30 |
| JP2021531831A (ja) | 2021-11-25 |
| CN113039289B (zh) | 2025-11-07 |
| AU2019310636A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260071281A1 (en) | Gene signatures for predicting metastasis of melanoma and patient prognosis | |
| US11015190B2 (en) | Method of treating a patient having renal cancer | |
| AU2020202536B2 (en) | Methods For Predicting Risk Of Metastasis In Cutaneous Melanoma | |
| AU2019263297B2 (en) | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma | |
| WO2021155377A1 (en) | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| AU2009349220A1 (en) | Methods of predicting clinical outcome in malignant melanoma | |
| EP4196615A1 (en) | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma | |
| HK40046957B (en) | Gene signatures for predicting metastasis of melanoma and patient prognosis | |
| HK40046957A (en) | Gene signatures for predicting metastasis of melanoma and patient prognosis | |
| CA3098152A1 (en) | Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220228 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240719 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240726 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240827 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250103 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250207 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250207 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250714 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250714 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260211 |